Skip to main content
. Author manuscript; available in PMC: 2015 Mar 18.
Published in final edited form as: Cardiovasc Drugs Ther. 2013 Dec;27(6):499–510. doi: 10.1007/s10557-013-6487-4

Table 1.

Body and cardiac masses, and echocardiographic results 14 weeks after surgery

Untreated
DHA treated
Sham Heart failure Sham Heart failure
Body mass (g) 411±8 390±7 437±5 403±7
Atria mass (mg) 57±5 210±13* 61±4 189±14*
RV mass (mg) 198±7 413±12* 225±7 374±19*
LV mass (mg) 876±18 1,282±34* 943±19 1,298±39*
Echocardiography:
 Heart rate (bpm) 359±7 342±5 349±12 337±5
 End Diastolic Diameter (mm) 7.5±0.2 8.3±0.2# 7.7±0.2 8.4±0.2#
 End Systolic Diameter (mm) 4.3±0.2 5.9±0.2* 4.3±0.2 5.4±0.2*
 End Diastolic Volume (μL) 494±47 641±42* 470±55 625±47#
 End Systolic Volume (μL) 90±20 228±17* 96±22 183±19#
 Ejection Fraction (%) 81.9±2.1 64.2±1.8* 81.0±2.3 71.5±1.8#
*

P <0.001

#

P <0.05 compared to sham within the same dietary group,

P <0.01 vs. the untreated heart failure group

Groups sizes were 15 and 20 for the untreated sham and heart failure groups, respectfully, and 14 and 20 for the DHA treated sham and heart failure groups, respectfully